Cortese, Rosa; Carrasco, Ferran Prados; Tur, Carmen; Bianchi, Alessia; Brownlee, Wallace; De Angelis, Floriana; De La Paz, Isabel; ... Ciccarelli, Olga; + view all Cortese, Rosa; Carrasco, Ferran Prados; Tur, Carmen; Bianchi, Alessia; Brownlee, Wallace; De Angelis, Floriana; De La Paz, Isabel; Grussu, Francesco; Haider, Lukas; Jacob, Anu; Kanber, Baris; Magnollay, Lise; Nicholas, Richard S; Trip, Anand; Yiannakas, Marios; Toosy, Ahmed T; Hacohen, Yael; Barkhof, Frederik; Ciccarelli, Olga; - view fewer (2022) Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology 10.1212/WNL.0000000000201465. (In press).

Preview

Text WNL.0000000000201465.full.pdf - Accepted Version Download (739kB) | Preview

Abstract

BACKGROUND AND OBJECTIVES: Relapsing remitting multiple sclerosis (RRMS), aquaporin4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may have overlapping clinical features. There is an unmet need for imaging markers that differentiate between them when serologic testing is unavailable or ambiguous. We assessed whether imaging characteristics typical of MS discriminate RRMS from AQP4-NMOSD and MOGAD, alone and in combination. METHODS: Adult, non-acute patients with RRMS, APQ4-NMOSD, MOGAD and healthy controls, were prospectively recruited at the National Hospital for Neurology and Neurosurgery (London, UK), and the Walton Centre (Liverpool, UK) between 2014 and 2019. They underwent conventional and advanced brain, cord and optic nerve MRI, and optical coherence tomography. RESULTS: A total of 91 consecutive patients (31 RRMS, 30 APQ4-NMOSD, 30 MOGAD) and 34 healthy controls were recruited. The most accurate measures differentiating RRMS from AQP4-NMOSD were the proportion of lesions with the central vein sign (CVS) (84% vs. 33%, accuracy/specificity/sensitivity: 91/88/93%, p<0.001), followed by cortical lesions (median: 2 [range: 1-14] vs. 1 [0-1], accuracy/specificity/sensitivity: 84/90/77%, p=0.002), and white matter lesions (mean: 39.07 [±25.8] vs. 9.5 [±14], accuracy/specificity/sensitivity: 78/84/73%, p=0.001). The combination of higher proportion of CVS, cortical lesions and optic nerve magnetization transfer ratio reached the highest accuracy in distinguishing RRMS from AQP4-NMOSD (accuracy/specificity/sensitivity: 95/92/97%, p<0.001).The most accurate measures favouring RRMS over MOGAD were: white matter lesions (39.07 [±25.8] vs. 1 [±2.3], accuracy/specificity/sensitivity: 94/94/93%, p=0.006), followed by cortical lesions (2 [1-14] vs. 1 [0-1], accuracy/specificity/sensitivity: 84/97/71%, p=0.004), and retinal nerve fibre layer thickness (RNFL) (mean: 87.54 [±13.83] vs 75.54 [±20.33], accuracy/specificity/sensitivity: 80/79/81%, p=0.009). Higher cortical lesion number combined with higher RNFL thickness best differentiated RRMS from MOGAD (accuracy/specificity/sensitivity: 84/92/77%, p<0.001). DISCUSSION: Cortical lesions, CVS and optic nerve markers achieve a high accuracy in distinguishing RRMS from APQ4-NMOSD and MOGAD. This information may be useful in clinical practice, especially outside the acute phase and when serologic testing is ambiguous or not promptly available. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that selected conventional and advanced brain, cord, and optic nerve MRI and OCT markers distinguish adult patients with RRMS from APQ4-NMOSD and MOGAD.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as CSVJSONXML

Archive Staff Only

View Item